For HER2-positive breast cancer, commonly used neoadjuvant chemotherapy regimens include anthracycline and taxane-based treatments, supplemented with HER2-targeted therapies such as trastuzumab and/or pertuzumab. Here, ERBB2 is linked to breast carcinoma.